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Abstract
Non-adherence to assigned treatment is a common issue in cluster randomised
trials (CRTs). In these settings, the efficacy estimand may be also of inter-
est. Many methodological contributions in recent years have advocated using
instrumental variables to identify and estimate the local average treatment
effect (LATE). However, the clustered nature of randomisation in CRTs adds
to the complexity of such analyses.
In this paper, we show that under certain assumptions, the LATE can be
estimated via two-stage least squares (TSLS) using cluster-level summaries of
outcomes and treatment received. Implementation needs to account for this,
as well as the possible heteroscedasticity, to obtain valid inferences.
We use simulations to assess the performance of TSLS of cluster-level sum-
maries under cluster-level or individual-level non-adherence, with and without
weighting and robust standard errors. We also explore the impact of adjusting
for cluster-level covariates and of appropriate degrees of freedom correction
for inference.
We find that TSLS estimation using cluster-level summaries provides esti-
mates with small to negligible bias and coverage close to nominal level, pro-
vided small sample degrees of freedom correction is used for inference, with
appropriate use of robust standard errors. We illustrate the methods by re-
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analysing a CRT in UK primary health settings.
Keywords: Cluster randomised trials, non-adherence, local average treatment ef-
fect, instrument variable, cluster-level analysis.
1 Introduction
Cluster randomised trials (CRTs), which randomise groups of individuals, are com-
mon in public health and primary care. The adoption of this design is often justified
given the reduction of “cross-over contamination” between the experimental arms
and improved adherence with allocated treatment [1–3]. Nevertheless, treatment
non-adherence is as common in CRTs as it is in individually randomised trials [4].
Dealing with non-adherence is more challenging because there are at least two levels
at which deviations from protocol can occur, e.g. cluster or individual level [5]. We
say that adherence is at the cluster-level if all individuals within a cluster receive
the treatment the cluster was randomised to. In contrast, we say that adherence
is at the individual-level, if the treatment received varies across individuals within
the same cluster, so that some individuals received the treatment allocated to their
cluster, while others did not.
The standard analysis of randomised clinical trials is intention-to-treat (ITT), which
compares average outcomes across randomised groups. However, if the effect of
treatment received is confounded, in the sense that there are measured and unmea-
sured common causes of receiving treatment and experiencing the outcome, the ITT
provides the causal effect of being offered, rather than of receiving, the treatment.
An ITT analysis with poor adherence may dilute a true treatment effect [6]. Re-
cently, there has been an increased interest in estimating other estimands alongside
the ITT, as highlighted by the International Council for Harmonisation (ICH) ad-
dendum to guideline E9 (Statistical Principles for Clinical Trials). Amongst them,
the causal effect in those adhering to treatment has been singled out as being of
interest for patients [7].
In the presence of unmeasured confounding, instrumental variable (IV) methods
can estimate consistently the causal effect of an exposure under certain assumptions
[8,9]. An IV is a variable which is correlated with the exposure but is not associated
with any confounders of the exposure–outcome association, nor is there any pathway
by which the IV affects the outcome, other than through the exposure.
Since randomised treatment is usually a valid instrument, IV methods have been
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proposed to estimate the treatment causal effect in the context of randomised clini-
cal trials affected by non-adherence [10,11]. The population to which an IV estimate
applies however, depends on the assumed behaviour of the instrument [9]. When, as
it is often the case, randomised treatment influences treatment received monotoni-
cally [9], in the sense that the level of treatment received is greater when randomised
to treatment, than when randomised to the control (the precise technical definition
will be given shortly), IV methods lead to estimating the causal effect among the
adherers, known as the local average treatment effect (LATE) or complier-average
causal effect (CACE).
This estimand can be estimated via the ratio estimator or the two-stage least squares
(TSLS) approach [12]. The later consists of a “first stage”, which regresses treat-
ment received on randomised treatment, and a “second stage”, which models the
outcome on the predicted treatment received. Additional covariates can be included
in each stage to control for measured confounding or increase precision. The regres-
sion coefficient for the predicted treatment received in the second stage model is a
consistent estimator of the LATE, provided that the first stage model is a linear
regression, containing all the variables appearing in the second stage [13, 14].
Extensions of this approach for the estimation of LATE in CRTs have been proposed,
ranging from a TSLS of individual-level data with variance inflation by the design
effect factor [15], to multilevel mixture models that include the latent compliance
class membership as a regressor and a random effect for cluster [16, 17]. Schochet
[18] uses cluster-level (CL) summaries for both treatment received and outcome to
construct a ratio estimator.
In this paper we focus on TSLS estimation applied to CL outcome summaries. Sim-
ilar to [18], this approach exploits well-known methods from cluster-level analysis,
which consist of calculating for each cluster a relevant summary measure of the
individual-level outcomes, such as means or proportions, and then analysing these
using appropriate statistical methods, such as regression. Because each cluster pro-
vides only one data point, the units of analysis can be considered to be independent,
but the procedure is inefficient [19]. Estimation by weighted least squares, where
the weights are defined either by the cluster size or by the so-called minimum vari-
ance weights can improve efficiency [15]. Comparing these alternative estimation
strategies for the implementation of TSLS estimation using CL data is the focus of
this paper.
The rest of the paper proceeds as follows. Section 2 provides an overview of cluster
level analysis methods, defines the estimand of interest, the LATE, and introduces
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the identification assumptions and the different cluster-level TSLS approaches. Sec-
tion 3 presents the simulations performed to compare the finite-sample performance
of the methods considered. In Section 4 we illustrate the methods by re-analysing
the TXT4FLUJAB trial, a UK based CRT evaluating the effectiveness and efficacy
of text messaging influenza vaccine reminders in increasing vaccine uptake amongst
patients with chronic conditions [20]. Section 5 concludes with a discussion.
2 Methodology
Consider a two-arm CRT, with n participants, indexed by i, in J clusters, indexed
by j, each of size nj . Let Zj denote the binary treatment randomly allocated at the
cluster-level with probability 0.50. Let Yij denote the continuous or binary outcome,
and Dij ∈ {0, 1} be the treatment received by individual i in cluster j. Let Wj and
Xij be baseline covariates at cluster and individual-level, respectively (which can be
vectors of variables).
With a slight abuse of notation, we let Yj denote the CL outcome (mean or pro-
portions), i.e. Yj =
1
nj
nj∑
i=1
Yij, hereafter referred to as the unadjusted CL outcome.
Analogously, let Dj denote the unadjusted CL treatment received, Dj=
1
nj
nj∑
i=1
Dij.
In the cluster-level adherence settings, Dij is constant within clusters, and therefore
Dj is binary. In contrast, when non-adherence is at the individual level, Dj is a con-
tinuous measure that varies from 0 to 1, representing the proportion of individuals
receiving the active treatment in cluster j.
2.1 Cluster-level analysis
The unadjusted CL analysis, uses simple CL summary statistics as the outcomes in
subsequent analyses. Let σ2 denote the variance of Yij, which can be decomposed
as σ2 = σ2ǫ + σ
2
υ, where σ
2
υ is the between-cluster variance and σ
2
ǫ the within-cluster
variance. The intra cluster correlation coefficient (ICC) for Yij is then ρy =
σ2υ
σ2υ+σ
2
ǫ
.
The variance of Yj is
Var(Yj)=σ
2
υ+
σ2ǫ
nj
=
1+ρy(nj−1)
nj
σ2. (1)
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Since CL outcomes are continuous (regardless of whether the original variable was
binary), they can be thought to be approximately normally distributed (if nj is suf-
ficiently large). Thus a linear regression with CL outcome Yj as dependent variable
and Zj as the explanatory variable can be fitted to estimate the ITT effects. In the
simplest setting, we have
Yj = α0 + αZZj + ηj (2)
where ηj is a random error term, assumed to be independently and identically dis-
tributed (i.i.d.), with mean 0. The ITT is estimated by αZ .
Efficiency is gained by estimating this model using generalised least squares (GLS),
with the weights being either the cluster size nj, or the so-called minimum-variance
(MV) weights given by [21],
ωj =
nj
1 + ρy(nj − 1)
.
MV weights are approximately equivalent to cluster size weights when ρy ≈ 0,
while if ρy ≈ 1, MV weights are approximately 1 [22]. These equivalences can have
practical implications when the variance of ηj cannot be consistently estimated, for
example if the number of clusters is small, so weighting by the cluster size or even
no weights, are viable alternatives. Where clusters are large, weighting by cluster
size is inefficient [23].
Since the ηj can be heteroscedastic especially when cluster sizes are very imbalanced,
the standard errors should be obtained using a method that takes this into account,
such as the Huber-White standard errors (HW SE) [24] which are consistent when
there is heteroscedasticity [25].
Finally, because each cluster now contributes only one observation, inference should
be based on the number of clusters J . Therefore, if p is the number of parameters
being estimated, hypothesis tests and confidence intervals (CIs) should be based
on appropriate distributions, for example tJ−p and not on normal-based approxi-
mations. We refer to this as small-sample degrees of freedom (SSDF) correction.
Where J is sufficiently large (> 40) normal approximations are adequate.
Regression analyses of CL summary outcomes can only adjust for CL covariates
directly, as using CL summaries for individual-level regressors is not appropriate [15].
However, where there is interest in adjusting for baseline covariates at the individual
level this can be done through a two-step procedure [26]. First, an individual-
level regression analysis of the outcome is performed incorporating all the relevant
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covariates into the regression model except for the treatment indicator and ignoring
clustering , e.g. with only one covariate Xij, we have:
Yij = λ0 + λ1Xij + e1ij . (3)
In the second step, the sample mean of the fitted residuals for this model ê1ij is
calculated for each cluster j,
ej =
1
nj
nj∑
j=1
ê1ij .
These are then used as CL outcomes in any subsequent analyses. See the Appendix
for the formulation for binary outcomes.
We refer to these summaries as adjusted CL outcomes (adCL). Regression mod-
els involving them can also be estimated by GLS, with inference based on normal
approximations or HW SEs and/or SSDF corrections, as before. Of note, if CL
covariates are used to compute adCL outcomes, the degrees of freedom (DF) must
be further reduced by the number of cluster-level regressors used to obtain the CL
outcome. No such adjustment is necessary for individual level variables [26]. In
this work, we only use adCL outcomes obtained by adjusting for individual level
variables. In the remainder, we denote the CL summary outcomes by Yj, whether
they are unCL or adCL, will be clear from the context.
2.2 LATE for CL data
2.2.1 Notation and technical assumptions
Denote by Yij(dj) the potential outcome that would manifest if, possibly contrary to
fact, the j-th cluster to which the individual belongs receives treatment dj, a vector
of length nj of 0s and 1s, where we are assuming no interference between clusters,
i.e. the potential outcomes and potential treatment received of individuals in the
j-th cluster are unrelated to the treatment status of individuals in other clusters [5].
“No interference between clusters” is a special case of partial interference, where
individuals can be partitioned into groups such that interference does not occur
between individuals in different groups but may occur between individuals in the
same group [27]. This is commonly assumed in clustered randomised trials [16, 17].
We also assume conterfactual consistency : for j = 1, . . . , J , if Zj = z then Dij =
Dij(z) and Yij = Yij(z,Dij(z)), for all i = 1, . . . , nj .
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2.2.2 Estimand of interest and identification assumptions
Assuming no interference between clusters and consistency, allows us to define the
estimand of interest, the local average treatment effect [8].
In the setting considered here where both Zj and Dij are binary, the vector of
potential treatment received under alternative random allocation, (Dij(0), Dij(1))
partitions the participants in each cluster into four different compliance classes :
Cij = n (never-takers) if Dij(0) = Dij(1) = 0; Cij = a (always-takers) if Dij(0) =
Dij(1) = 1; Cij = c (compliers) if Dij(z) = z for z ∈ {0, 1}; and Cij = d (defiers) if
Dij(z) = 1− z for z ∈ {0, 1}.
The estimand of interest here is the so-called population complier average causal
effect (LATE), defined as
β = EjEi [{Yij(1, Dij(1))− Yij(0, Dij(0))}|Cij = c]
=
∑J
j=1
∑nj
i=1{Yij(1, Dij(1))− Yij(0, Dij(0))}{I(Dij(1) = 1, Dij(0) = 0)}∑J
j=1
∑nj
i=1 I(Dij(1) = 1, Dij(0) = 0)
(4)
This is said to be a “local” causal effect as it is conditional on the stratum of complier
individuals. For this reason, this is often referred to as the local average treatment
effect (LATE).
Following [5,28], we write the cluster version of the corresponding identification as-
sumptions [9] as follows:
(A1) Cluster unconfoundedness : Zj ⊥⊥ Dij(z), Yij(z,Dij(z)), z ∈ {0, 1}. This
is also known as cluster or group independence or cluster randomisation assumption.
(A2) Exclusion restriction at the individual level : Conditional on the treat-
ment received Dij = d, the treatment assignment Zj had no effect on the outcome.
In terms of potential outcomes we have:
Yij (1, d) = Yij (0, d) ∀d ∈ {0, 1}.
(A3) Instrument relevance: Also referred to as first stage assumption:
Zj is causally associated with treatment received Dij , i.e. Zj 6⊥⊥ Dij .
For point identification of local treatment effects, (A4) monotonicity of the treat-
ment mechanism is often assumed: Dij(1) ≥ Dij(0) , often informally referred to as
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“there is no defiers” [8]. Notice we need to assume this holds at the individual level
[28]. For the cluster-level non-adherence setting, where Dij does not vary within
clusters, then this becomes monotonicity at the cluster level Dj(1) = 1, Dj(0) = 0.
An extra assumption necessary when using adjusted CL outcomes is that the model
used to derive them is correctly specified.
2.2.3 Cluster and individual-level non-adherence
The population-level LATE estimand β can be thought of as a weighted average of
the cluster-specific LATE for each cluster j, βj , namely
β =
J∑
j=1
ψjβj , (5)
where
βj = Ei [Yij(1, Dij(1))− Yij(0, Dij(0))|Cij = c]
=
1
nc,j
nj∑
i=1
[{Yij(1, Dij(1))− Yij(0, Dij(0))}{I(Dij(1) = 1, Dij(0) = 0)}] , (6)
with nc,j is the number of individual-level compliers in each cluster j, assumed here to
be > 0 for all clusters. The weights corresponding to each βj are ψj =
nc,j
∑J
j=1 nc,j
, that
is the number of cluster-specific compliers divided by the total number of compliers.
This result is useful when interpreting the estimates obtained using CL summaries.
We first note that the Wald estimand applied to CL summaries, βCL does not always
correspond to the population LATE β. The former can be expressed as [5]:
βCL =
E[Yj|Zj = 1]− E[Yj|Zj = 0]
E[Dj |Zj = 1]− E[Dj |Zj = 0]
(7)
In the case where treatment received is at the cluster level (i.e. cluster-level ad-
herence), this CL Wald estimand indeed can be interpreted as a the population
LATE.
In the case where non-adherence varies at the individual level, it can be shown that
βCL =
∑J
j=1 ψCL,jβj where the CL-weights are ψCL,j =
nc,j/nj∑
j nc,j/nj
, i.e. the normalised
proportion of individual compliers in each cluster [28]. So, CL-LATE βCL identifies
8
the population LATE , equation (5), only if (i) the cluster sizes nj are identical for
all j, or (ii) the cluster-specific LATE βj are homogeneous across all clusters.
In the remainder, with individual-level non-adherence we assume that every cluster
has the same cluster-specific LATE, but allow for the cluster sizes to vary. If this is
not the case, the CL-LATE βCL identifies a weighted average of the heterogeneous
cluster-specific LATE, because of clusters with the same proportions of compliers
are weighted the same, without accounting for the cluster size.
2.3 TSLS for CL data
The conditional expectations appearing in the Wald estimand (equation 7) can be
estimated via TSLS regression of the CL summaries (referred to as CL-TSLS). CL-
TSLS is most easily explained for settings without weights or covariate adjustment.
The first stage fits a regression to CL treatment received Dj on treatment assigned
Zj. Then, in a second stage, a regression for the CL outcome, (either unCL or adCL),
on the predicted treatment received is fitted. Crucially both first and second stages
must be linear models for the TSLS estimator to be guaranteed to be consistent
[14, 29]. We have:
Dj = γ0 + γZZj + ω1j
Yj = β0 + βIV D̂j + ω2j (8)
where ω1j and ω2j are assumed i.i.d. with mean zero and constant variance, with
ω1j ⊥⊥ ω2j, and β̂IV is the estimate of CL-LATE.
Cluster-level covariates can be included to increase precision. For example, with one
CL covariate Wj , we have
Dj = γ0 + γZZj + γWWj + υ1j
Yj = β0 + βIV D̂j + βWWj + υ2j (9)
where the error terms are as before.
The asymptotic standard error for the TSLS estimator is given in [8], and imple-
mented in commonly used software packages.
As with the cluster level estimation of ITT, where the number of clusters is small,
the CIs are constructed using a t distribution with degrees of freedom equal to J−p,
where p is the number of parameters estimated by the second stage (i.e. the SSDF
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correction). As before, MV or cluster size weights can be used to increase efficiency.
Finally, the error terms in the CL-TSLS are assumed to be homoscedastic. Where
this is not a sensible assumption, Huber-White SEs should be used [30].
3 Simulation study
We now perform a simulation study comparing the finite sample performance of
TSLS estimation applied to CL data. We simulate CRT individual-level data with
one-way non-adherence, at either cluster or individual level. With a fixed expected
total sample size equal to 1000, we vary the number of clusters J , and the average
cluster size nj . The marginal ICC of Y also takes two values. The effect of individual
and cluster level variables on the outcome and the treatment received also varies, so
that the strength of the confounding is either low or high, while the value of the true
LATE also has two levels. Table 1 summarises the factorial design and the values
taken by the different levels.
More specifically, we simulate cluster randomised treatment Zj ∼ Bern(0.5) and
two independent baseline covariates, a cluster-level covariate Wj ∼ N(0, σ
2
W ) and
individual-level covariate Xij ∼ N(0, σ
2
X) with a moderate ICC ρX = 0.05, and
σ2W = σ
2
X = 0.08.
We then generate a binary adherence class indicator variable Cij , which is considered
as latent. For settings where adherence is at the cluster level, this is constant within
clusters, under the following model
Cij = Cj ∼ Bern(πj) with πj = P (Cj=1)
logit(πj) = λ0 + λWWj,
with λW = 0.05 equivalent to an odds ratio OR ≈ 1.05 per unit increase in W
(denoted “small effect”) and λW =0.7 equivalent to OR ≈ 2 (“large effect”).
For settings with individual-level adherence, the data generating model is
Cij ∼ Bern(πij) with πij = π = P (Cij = 1)
logit(πij) = λ0 + λWWj + λXXij + ζj
ζj ∼ N
(
0, σ2ζ
)
with σ2ζ =π
2/3, so that the ICC for compliance is ρC=σ
2
ζ/(σ
2
ζ + π
2/3)=0.50.
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We derive treatment received at the individual level as
Dij = ZjCij,
so that those individuals in clusters randomly allocated to control have always con-
trol treatment, but those in clusters randomised to the active intervention can switch
to the control treatment, depending on their adherence class.
We finally generate continuous outcome Yij, under the exclusion restriction assump-
tion,
Yij = β0 + βCCij + βCZCijZj + βWWj + βXXij + υj + ǫij (10)
with υj ∼ N(0, σ
2
υ) and ǫij ∼ N(0, σ
2
ǫ ), where the values for σ
2
υ and σ
2
ǫ are chosen
such that the marginal ICC for Y has the corresponding value according to the
simulated scenario, given that Var(Yij) = σ
2 = 1. The choice of the parameters’
values is reported in Table 1.
Table 1: Factorial design of the data generating processes and values taken by the pa-
rameters in the simulations.
Parameter Label Level Value
CRT size
n Total number of individuals Moderate ≈ 1 000
J Number of clusters and Moderate clusters J = 50, nj ∼ Poi(20)
nj individuals per cluster Few large clusters J = 10, nj ∼ Poi(100)
Baseline variables
Wj Cluster-level variable - Wj ∼ N(0, 0.08)
ρX ICC for Xij Moderate 0.05
Xij Individual-level variable - Xij = Xj + eij , Xj ∼ N(0, 0.004),
eij ∼ N(0, 0.076)
Adherence to treatment
pi Expected probability Moderate 0.60 (cluster-level adherence)
of adherence 0.85 (individual-level adherence)
λW , λX Wj and Xij effects on Small λW = 0.05, λX = 0.05
log odds of adherence Large λW = 0.70, λX = 0.70
Cj Cluster-level adherence - Bern[expit(λ0 + λWWj)]
class
Cij Individual-level - Bern[expit(λ0 + λWWj+
adherence class λXXij + ζj)]
ζj Cluster-level random effects - ζj ∼ N(0, pi
2/3)
ρC ICC for Cij Moderate 0.50
Outcome
β0, βC β0=0, βC=0
βW , βX Wj and Xij effects Small βW=0.1 SD, βX=0.1 SD
Continued on next page
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Table 2 Continued
Parameter Label Level Value
on outcome Yij Large βW=0.4 SD, βX=0.4 SD
βCZ True LATE Small, Large 0.1 SD, 0.4 SD
ρY ICC for Yij Small, Large 0.05, 0.20
a
SD: standard deviation of the outcome Y , σ = 1.
We need the data generating process to result in randomised treatment Z being
a valid IV, but some combinations may result in weak instruments, for example,
cluster-level non-adherence settings, with only 5 clusters per arm, and the proportion
of non-adherent clusters set at 40% (the median proportion of non-adherent clusters
reported in [4] being 44.8%). Thus, after creating each dataset, we perform an
unadjusted first stage regression of Dj on Zj and reject simulated datasets where the
resulting F−statistic is < 10, (Staiger & Stock’s rule of thumb for weak instruments
[31]). We continue this process until we have 2500 datasets per scenario.
Estimation in each scenario involves using unadjusted CL summary of treatment
received in the first-stage, and either unadjusted or individual-level variable adjusted
CL summary outcomes, for the second stage. Each regression in the TSLS was fitted
via OLS or GLS, the latter with either cluster size or MV weights. We also consider
TSLS where each stage model is either unadjusted or adjusted for a cluster-level
variable. Finally, we obtain SEs assuming homoscedasticity or HW SEs, and SSDF-
based or normal approximation CIs. An summary is given in Table 2. Details of
the Stata code used for analysis are found in the web-Appendix.
Table 2: Overview of TSLS estimation and inference strategies used in the simulation
study
Analyses features Levels
CL outcome Unadjusted Adjusted for Xij
TSLS adjusted for Wj : No Yes
Weights none (i.e. OLS) CS MV
SE estimation: Normal theory HW SE
SSDF correction: No Yes
CL: cluster level; HW: Huber-White; CS weights: cluster-size weights; MVW: minimum
variance weights; SE: standard error; SSDF: Small sample degrees of freedom correction
The performance criteria used are empirical bias and coverage rates of the 95% CIs
over the 2500 replicate datasets per scenario. For the bias, we construct a 95% CI
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using its Monte Carlo Error (MCE). The coverage rate sampling error given the
size of the simulation results in a valid range between 94.1% and 95.9%. See the
Appendix for the formal definitions.
3.1 Results
We present the results by plotting the empirical bias with the MCE-based CIs. The
coverage rate valid range is represented by horizontal dashed lines.
Figure 1 and Figure 2 report the empirical bias and 95% CI coverage resulting from
each of the different CL-TSLS estimators, when adherence is at cluster or individual
level respectively, and for scenarios where the true LATE is large (0.4 SD). The
corresponding figures for small true LATE are in the Appendix, Figure 7 and 8.
Each figure reports results where J = 10 (Panel A, top) or J = 50 (Panel B), and
with the ICC for Y , ρY , is either small (first three columns) or large (last three
columns). In each cell, the results for alternative combinations of TSLS (unad-
justed/adjusted for Wj) applied to unCL or adCL outcomes are plotted along the
horizontal axis.The different data generation scenarios are identified by ∗,+,×, and
◦, corresponding to varying strengths of the effects of X and W on Y .
We see that all CL-TSLS estimators show finite sample bias, regardless of whether
the non-adherence was at the cluster or individual level and whether the CL sum-
mary for Y was adjusted or unadjusted, or Wj was included or not in the TSLS
regressions. The bias is more severe when the ICC for Y is larger (right hand side
of each Figure), especially if the number of clusters is small (Panel A). The bias is
somewhat attenuated when we adjust for Wj in the TSLS, and the non-adherence is
at the cluster-level (Figures 1 and 7). In contrast, for settings with individual-level
non-adherence, this adjustment instead increases the bias, especially if W has only
a small confounding effect. In these scenarios, the estimates exhibit a small but
statistically significant bias, which disappears when the number of clusters is larger
(Figures 2 and 8). In general, the bias is not affected by the choice of weighting
strategy, nor by whether ρY is small or large.
Comparing the results of the 2nd, 3rd, and 4th rows in each panel (Figures 1 and 2),
we see that the coverage rate is affected by the choice of SE estimation and also by
whether SSDF correction is used. When the number of clusters is small, an SSDF
correction must be used as failing to do so results in under-coverage (Panels A). The
low coverage is more serious when TSLS adjusts for W (second and fourth set of
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results in each panel).
Overall, the results in Panel A of each figure show that using HW SE or not has little
to no impact if there is no SSDF correction. However, when the SSDF correction is
used for settings with cluster-level non-adherence, large ρY , and large true LATE,
but where only X is strongly associated with Y , using unCL outcomes leads to
under-coverage, regardless of weighting or SE method (Figures 1 and 7, 3rd and
5th rows of Panel A, right hand side columns). The use of adCL outcomes (i.e.
where the CL outcome is the residual after adjusting for individual level variable X)
recovers coverage close to nominal. This is not the case when the non-adherence is
at the individual level, and both W and X are confounders of the causal effect the
treatment received D and the outcome Y in the data generating process.
In both cluster and individual-level non-adherence settings, it can be seen that using
MV weights increases the coverage by a small fraction, when compared with cluster
size weights, especially for scenarios with J = 50 and large ρY . However, since MV
weights require an estimate of the cluster-level variance, and this is badly estimated
when the number of clusters is small (J = 10), we can see that MV weights are less
efficient than using either no weights or cluster size weights. This is most clearly
seen when no HW SE correction has been used.
We can also see that when SSDF correction is used, then not using HW SE can result
in small over-coverage especially for cluster-level non-adherence settings, which is
improved when HW SE are used (Figures 1 and 7, 3rd and 5th rows of Panel A).
When J = 50 (Panel B), the use of SSDF-based distributions is not expected to
make any material difference, and this is indeed the case. The impact of using HW
SE or the different weighting strategies is also minimal.
3.2 Additional simulations
Two extra additional scenarios are now considered to investigate the sensitivity of
the CL-TSLS performance to number of clusters and cluster size imbalances, at both
cluster and individual level adherence, but focusing on settings where confounding
is strong with a large true LATE.
In the first additional simulation, we explore the impact that the outcome ICC and
the number of clusters have on bias, while leaving the expected total sample size
fixed (= 1000).
We consider two marginal ICC for Yij (ρY = 0.05 and ρY = 0.80) and three average
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cluster size (nj = 20, 10 and 2.5, corresponding to whether the number of clusters
varied from J = 50, 100 or 400), which includes one of the scenarios previously
considered in the main simulations for comparison. Though CRTs rarely have ICCs
above 0.10 [32], the value of ρY = 0.80 is included to evaluate the performance of
the methods in extreme settings.
In the second additional set of simulations we explore the effect of high cluster size
imbalances. While keeping the average sample size equal to 1000, and J = 10 or
50, we create high cluster size imbalance using a Pareto distribution to generate
the cluster sizes [33]. The Pareto distribution parameters are chosen so that ap-
proximately 40% of the clusters have a size below 15, and 60% a size above 15,
while the average cluster size is 20 and the minimum cluster size is 10, resulting in
approximately 1.8 for the shape and 9.1 for the scale.
3.2.1 Results
Figures 3 and 4, corresponding to cluster and individual level non-adherence settings,
show that for a fixed number of clusters (cells in the same row), the bias increases
with increasing ICC for Y , but that as the number of clusters increase (moving
down the column in the Figure), CL-TSLS results in negligible mean bias, even a
very large ρY . It is well known that TSLS is only asymptotically unbiased, and with
CL analyses, we expect the asymptotics to depend on the number of clusters, and
not the number of individuals. Nevertheless, the CL-summaries treated as outcomes
for the two models involved in TSLS contain less “information” when the ICC is
higher, which translates into a larger number of clusters being necessary for the bias
to be negligible.
The impact of high cluster size imbalance is reported in Figures 5 and 6, where
non-adherence is at the cluster and individual level respectively. We see that when
J = 10 (Panel A), even with SSDF correction, failure to use HW SE results in under-
coverage when using cluster size weights, which is especially pronounced when ρY
is large. This is because cluster size weights are known to perform well when the
cluster level residuals are homoscedastic, which is unlikely when cluster sizes are
very imbalanced [15]. This also explains why, using HW SE brings the coverage
close to nominal levels. This pattern is also observed at J = 50 (Panel B).
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4 Illustrative example
We now illustrate the methods in practice by applying each in turn to the analysis
of the TXT4FLUJAB trial. This was a CRT of general practices in England aiming
at estimating the effect of text messaging influenza vaccine reminders on increasing
vaccine uptake in patients with chronic conditions, carried during the 2013 influenza
season [20]. General practices (GPs) were stratified by the type of software used
for text messaging and randomised to either standard care (control group, 79 GPs
and 51136 patients) or a text messaging campaign (active group, 77 GPs and 51121
patients). Practices were not blinded to their allocation. GPs were the unit of
analysis and the outcome of interest was the proportion of influenza vaccine uptake
at the GP level.
Influenza vaccination within the GPs was automatically recorded in the clinical
system from which the data were extracted, so there are no missing data.
Since non-adherence was anticipated, the original statistical analysis plan specified
obtaining by IV regression an efficacy estimate at the GP level [20]. The origi-
nal publication reported an estimated increase in vaccine uptake from texting re-
minders of 14.3% (95% CI –0.59% to 29.2%) [20], after dichotomising adherence at
the cluster-level as either 100% of eligible patients, compared with texting < 100%.
Adherence to the intervention at the individual level could not be measured for all
practices because it was recorded in a usable form only for GPs using a specific
software. Therefore, for these re-analyses, we restrict the dataset to 116 GPs (58
in the intervention and 58 in the standard care arm) for which individual-level
adherence data are available. Six of the 58 practices (10%) in the intervention arm,
did not send any reminders. Conversely, 21 of the 58 practices (36% in the standard
care arm actually sent a reminder to at least one patient. Hence non-adherence is
two-sided. It also varies at the individual level. The median (range) of percentage
of non-adherence at the GP level was 0% (0%-78.4%) and 21.0% (0%-83.5%) in the
control and active group, respectively (Table 3).
The characteristics of the GPs and of the patients included in these analyses are
comparable across trial groups (Table 3); further the marginal ICC for individual-
level outcome (vaccination) and treatment received (text message reminder) was
0.03 and 0.84 on the log-odds scale, respectively.
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Table 3: Baseline characteristics and percentages of non-adherence for the
TXT4FLUJAB trial.
Characteristics Control Active
Practice-level characteristics
Number of practices, n (%) 58 (100.0) 58 (100.0)
Open on weekends, n (%) 39 (67.2) 37 (63.8)
Patients per practice, median (range) 660 (148-1 678) 684 (79-3 022)
Patient-level characteristics
Number of patients, n (%) 40 633 (100) 41 073 (100)
Male, n (%) 20 752 (51.1) 21 012 (51.2)
Has any disease, n (%) 39 244 (96.6) 39 672 (96.6)
Age, median (range) 50 (18-64) 50 (18-64)
Active treatment received
Patients receiving text message reminders, n (%) 2 628 (6.5) 11 113 (27.1)
Practices sending text message reminders, n (%) 21 (36.2) 52 (80.7)
% of patients in each GP receiving reminders, 0 (0-78.4) 21.0 (0-83.5)
median (range)
For our re-analysis, we begin by discussing the plausibility of the identification
assumptions. The unconfoundedness assumption of the CL randomised treatment is
satisfied by design. To check whether cluster randomisation is a relevant instrument,
we perform a test on the first stage of the CL-TSLS. The corresponding F-statistic
is F (1, 114) = 28.7 > 10 thus passing Staiger and Stock’s rule of no null first-stage
[31].
The exclusion restriction at the individual level implies that there is no other mech-
anism by which the GP being randomised to sending text vaccination reminders
can affect a patient’s actual vaccination uptake beside via the sending of the mes-
sage. This assumption needs further justification, as in principle, a GP randomised
to send reminders can be more conscious of the risks the patients face during the
influenza season and use other means to remind at-risk patients, either in person,
by post or by putting out flyers and posters in the clinic. So, it is possible that
there are patients who do not receive text reminders and yet are prompted to get
vaccinated by other means, by virtue of their practice being in the active group.
However, flyers, posters and postal letters already form part of regular care, so we
believe they do not really vary by whether the GP is randomised to the active group.
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The monotonicity assumption (that there are no defiers) also seems plausible as GPs
randomised to the active group were more likely to send a text message reminder
than those in the control group (see Table 3).
Finally, there is a small risk of interference. The cluster defined by GP practice
should minimise this, as we only need to assume no interference at the cluster
level, but it could be plausible that patients interact with those outside their GP,
so that the exposure to a text message reminder of one patient may indeed affect
the potential outcome, in this case, influenza vaccination of another patient from a
different GP. The risk is small as usually close family members belong to the same
general practice.
CL-TSLS on unadjusted CL outcomes was implemented adjusting and not adjusting
for a baseline CL covariate, namely whether the clinic was open on the weekends
(yes/no). Table 4 shows the CL-LATE estimates (expressed as mean risk differ-
ences), with 95% CIs and p-values obtained via different weighting strategies, and
corrections.
Using cluster size weights results in different point estimates from the rest. This was
expected as there is substantial cluster size imbalance (cluster size range: 148–1678
in the control group and 79–3022 in the active group (Table 3). The results obtained
using no weights or MV weights leads to point estimates that are very close to those
found in the original publication [20].
In terms of inference, the use of SSDF correction in calculating CIs is not important,
as the number of clusters is large, but the HW SEs paired with MV weighting
provides efficiency gains, especially for the adjusted CL-TSLS analyses. Overall
however, the CIs are still very wide.
These results suggest that there is weak evidence that receiving a text reminder
increases the expected proportion of patients within a compliant practice that get
vaccinated against influenza by 14% (95% CI: −0.5 to 30%, p = 0.065, based on the
adjusted CL-TSLS using MV weights and normal-based CI with HW SEs estimate).
Contrast this with the unadjusted CL-summaries mean risk differ zence ITT esti-
mate, which indicates a 2.89% increase (95% CI −0.17 to 5.95, p = 0.064), high-
lighting the dilution effects deriving from the non-adherence.
One of the disadvantages of TSLS is lack of efficiency. Adjusting for individual-level
baseline covariates may help obtaining narrower CIs. Since CL-TSLS cannot adjust
for individual level covariates, we now perform the analyses using adCL summary
outcomes, generated by adjusting for gender, age and the presence of disease. Results
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are reported in Table 5 in the Appendix. The results do not materially change (weak
evidence of a 13% increase vaccination uptake), possibly because these individual
level covariates are not strongly associated with the outcome.
Our illustrative example is limited by the availability of baseline cluster-level vari-
ables. Since there was only one CL-variable recorded, the impact of covariate ad-
justment on the CL-TSLS is negligible. Other limitations of these results include
the possibility of measurement error, for if patients received their influenza vaccine
outside the practice, this would not have been recorded in the system, unless the
patient informed their GP.
Table 4: LATE of text message reminders to receive flu vaccination on the uptake of flu
vaccine in the TXT4FLUJAB trial, using unadjusted CL-summaries
Unadjusted Adjusteda
LATE (95% CI) p LATE (95% CI) p
No weighting None 0.149 (-0.006,0.305) 0.060 0.148 (-0.078,0.303) 0.063
HW 0.149 (-0.006,0.305) 0.060 0.148 (-0.005,0.301) 0.058
SSDF 0.149 (-0.009,0.308) 0.065 0.148 (-0.012,0.308) 0.069
SSDF + HW 0.149 (-0.009,0.308) 0.065 0.148 (-0.009,0.305) 0.064
Cluster size None 0.071 (-0.065,0.207) 0.307 0.074 (-0.061,0.209) 0.284
weights HW 0.071 (-0.088,0.230) 0.382 0.074 (-0.077,0.225) 0.338
SSDF 0.071 (-0.068,0.209) 0.313 0.074 (-0.064,0.212) 0.292
SSDF + HW 0.071 (-0.091,0.233) 0.388 0.074 (-0.081,0.228) 0.346
Minimum- None 0.143 (-0.008,0.293) 0.064 0.142 (-0.009,0.293) 0.065
variance HW 0.143 (-0.006,0.291) 0.060 0.142 (-0.005,0.289) 0.058
weights SSDF 0.143 (-0.011,0.296) 0.069 0.142 (-0.012,0.297) 0.071
SSDF + HW 0.143 (-0.009,0.294) 0.065 0.142 (-0.008,0.293) 0.064
a Adjusted for whether clinic is opened during weekends.
HW: Huber-White; SSDF: small sample degrees of freedom.
5 Discussion
This paper demonstrates the use of TSLS regression applied to CL summaries as a
simple and valid method for obtaining estimates of the LATE in CRTs where non-
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adherence occurs at either the cluster or the individual level. The performance of
CL-TSLS with different weighting strategies (none, cluster size, minimum variance)
and methods for obtaining CIs (alternatively using or not Huber-White SEs and/or
SSDF correction).
We have demonstrated empirically through simulations that under the stated suffi-
cient assumptions for identification TSLS regression of CL summaries provides con-
sistent estimates of the causal treatment effect in the sub-population of compliers,
where non-adherence is at the cluster level. With individual-level non-adherence,
the additional assumption that the cluster-specific LATE is homogeneous across
clusters is required for CL-TSLS to identify the population LATE [28]. Moreover,
provided that an appropriate distribution with SSDF adjustment is used when the
number of clusters is small and Huber-White SEs are used if there is high cluster
size imbalance, valid 95% CIs can be constructed.
Our simulation study suggests that all weighting strategies perform similarly when
the number of clusters is not small. When the number of clusters is small, MV
weights tend to be badly estimated, and are not recommended; furthermore when
the cluster sizes are very variable, cluster size weights should not be used. Although
in the simulations the choice of weights did not affect the point estimates, these were
affected in the illustrative example. Overall our results show that, unless there are
very few clusters, or the outcome ICC is large, MV weighting performs well [23].
Although CL-TSLS is easy to implement, it suffers from being very inefficient. We
can see this in the illustrative example where all CIs for the CL-TSLS LATE es-
timates are much wider than those for the estimated ITT. There are two reasons
for this: CL-analyses are inefficient, unless the cluster sizes are (almost) equal [34],
and TSLS is known to be inefficient, although adjusting for baseline covariates can
ameliorate this [14]. In the context of CL-analysis it is only possible to include
cluster-level baseline covariates in the regressions [15]. However, we tested the per-
formance of CL outcome which are adjusted for individual-level covariates [26], and
showed that this indeed has the potential to improve efficiency in certain settings.
For CL-TSLS analyses, inference should be based on the number of clusters, with
CIs constructed by using t− distributions with DFs equal to J−p [35]. The outcome
ICC value is important too, with higher ICCs requiring a larger number of clusters
for the asymptotical arguments to work, as well as whether the cluster-level variances
are homoscedastic [15].
Other methods for estimating causal treatment effects in CRTs with non-adherence
at the individual level exist, in particular Kang and Keele [28] have recently proposed
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a finite-sample estimator that identifies the population LATE and obtains valid
inferences even when compliance is low.
We do not consider here situations where the identification assumptions are violated.
There are several options to study the sensitivity to departures from these assump-
tions. For example, if the exclusion restriction does not hold, a Bayesian parametric
model can use priors on the non-zero direct effect of randomisation on the outcome
for identification [36]. Since the models are only weakly identified, the results de-
pend strongly on the prior distributions. Alternatively, violations of the exclusion
restriction can also be handled by using baseline covariates to model the proba-
bility of compliance directly, within structural equation modelling via expectation-
maximisation framework [37, 38].
We have only focused on LATE estimands. These are often criticised because the
estimates obtained apply to the “compliers” in the population, and these cannot be
observed in practice, thus limiting applicability. However, LATE estimates may be
used to provide information about the average causal effect in the entire population
[39]. Moreover, the average treatment effect on the compliers is often of interest
to patients and medical decision makers, especially when they expect patients to
comply with the treatment [40].
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Figure 3: Bias of the CL-LATE for the extra simulation where non-adherence is at the
cluster-level and a large true LATE, with high ICCs and varying numbers of clusters.
Estimates are obtained via unadjusted or adjusted TSLS with different weights (none,
cluster size (CS) and minimum-variance (MV)). Number of clusters varies by rows and
ICC by column.
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Figure 4: Bias of the CL-LATE for the extra simulation where non-adherence is at the
individual-level and a large true LATE, with high ICCs and varying numbers of clusters.
Estimates are obtained via unadjusted or adjusted TSLS with different weights (none,
cluster size (CS) and minimum-variance (MV)). Number of clusters varies by rows and
ICC by column.
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Appendices
A Adjusted cluster-level summaries for binary data
For binary a standard logistic regression model is usually fitted for binary outcomes,
which assumes that
logit (πij) = log
(
πij
1− πij
)
= λ1 + λ2Xij (11)
LetMj and Mˆj be the observed and predicted number of successes in the jth cluster,
respectively. After fitting model (11), Mˆj is calculated as
Mˆj =
m∑
l=1
πˆij =
nj∑
i=1
expit
(
λˆ1 + λˆ2Xij
)
.
Then the observed and predicted numbers of success are compared by computing
a residual for each cluster. If we want to estimate the adjusted RD, the residual,
known as difference-residual, for each cluster is calculated as
ej = (Mj − Mˆj)/nj ,
and treated as a continuous outcome in any subsequent analyses.
31
B Performance criteria
Let the mean of the estimated LATE across the replicate datasets in each scenario,
indexed by l = 1, ..., L, with L = 2, 500 be
¯ˆ
βIV =
1
L
L∑
l=1
βˆIVl. The following criteria
were used to assess the performance of the methods investigated
(a) Empirical bias: estimated by
¯ˆ
βIV − βCZ .
(b) Monte Carlo error (MCE) of empirical bias =
√∑L
l=1
(
βˆIVl −
¯ˆ
βIV
)2
/[L(L− 1)].
(c) Coverage rate of the nominal of 95% CIs 1
L
∑L
l=1 I
(
|βˆIVl−βCZ | < 1.96si
)
,
where si denotes the model-based standard error for βˆIVl. The MCE of coverage
is
√∑L
l=1(0.95)(0.05)/L,which means that the expected range of the nominal
95% CIs is between 94.1% and 95.9%.
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C Results for adjusted CL summaries CL-TSLS
for TEXT4FLUJAB
Table 5: TSLS estimation of practice-level LATE of reminder text messaging to receive flu
vaccine on the percentage uptake of flu vaccine in the TXT4FLUJAB trial using adjusted
CL outcomes, adjusting for individual-level covariates gender, age and presence of disease.
Unadjusted Adjusteda
LATE (95% CI) p LATE (95% CI) p
No weighting None 0.133 (-0.016,0.282) 0.081 0.133 (-0.017,0.282) 0.082
HW (-0.016,0.282) 0.081 (-0.014,0.280) 0.077
SSDF (-0.019,0.285) 0.086 (-0.021,0.286) 0.089
SSDF + HW (-0.019,0.285) 0.086 (-0.018,0.283) 0.083
Cluster None 0.068 (-0.063,0.198) 0.310 0.071 (-0.058,0.200) 0.280
size weighting Huber-White (-0.081,0.216) 0.372 (-0.069,0.212) 0.320
SSDF (-0.065,0.201) 0.316 (-0.061,0.203) 0.288
SSDF + HW (-0.084,0.219) 0.378 (-0.073,0.215) 0.328
Minimum- None 0.128 (-0.017,0.273) 0.084 0.128 (-0.017,0.273) 0.084
variance weighting HW (-0.015,0.271) 0.080 (-0.014,0.269) 0.077
SSDF (-0.020,0.275) 0.090 (-0.021,0.277) 0.091
SSDF + HW (-0.018,0.273) 0.086 (-0.017,0.273) 0.083
a TSLS estimation was adjusted for weekend clinics (yes/no).
D Results for small true LATE
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